Cargando…

Decreased CD3-CD16+CD56+ natural killer cell counts in children with orbital myositis: a clue to disease activity

The study aimed to document the utility of the absolute number of natural killer cells as a biomarker in paediatric orbital myositis (OM). Extracted data from four children with OM included demographics, laboratory values, imaging and treatment response. Stored sera (−80°C) were tested for IgG4 leve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Briones, Melissa R, Morgan, Gabrielle A, Amoruso, Maria C, Rahmani, Bahram, Ryan, Maura E, Pachman, Lauren M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Paediatric Rheumatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604601/ https://www.ncbi.nlm.nih.gov/pubmed/28955482 http://dx.doi.org/10.1136/rmdopen-2016-000385

Ejemplares similares

Chronic and recurrent non-infectious paediatric-onset uveitis: a French cohort
por: Morelle, Guillaume, et al.
Publicado: (2019)

Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis
por: Huang, Bin, et al.
Publicado: (2020)

Soluble CD24 is an inflammatory biomarker in early and seronegative rheumatoid arthritis
por: Zheng, Xi, et al.
Publicado: (2023)

A Pediatric Case of Granulomatous Myositis and Response to Treatment
por: Abdul-Aziz, Rabheh, et al.
Publicado: (2021)

CD56(dim)CD16(dim) Natural Killer (NK) Cells: The Forgotten Population
por: Zimmer, Jacques
Publicado: (2020)

Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Ravelli, Angelo, et al.
Publicado: (2016)

Malignancy incidence in 5294 patients with juvenile arthritis
por: Zahedi Niaki, Omid, et al.
Publicado: (2016)

The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort
por: Sengler, Claudia, et al.
Publicado: (2015)

Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent
por: Woerner, A, et al.
Publicado: (2015)

Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage
por: Oliveira-Ramos, Filipa, et al.
Publicado: (2016)

Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children
por: Cabrera, Natalia, et al.
Publicado: (2016)

ProNGF-p75NTR axis plays a proinflammatory role in inflamed joints: a novel pathogenic mechanism in chronic arthritis
por: Minnone, Gaetana, et al.
Publicado: (2017)

Growing up with chronic arthritis: the confusing matter of classification
por: Guillaume-Czitrom, Séverine, et al.
Publicado: (2017)

ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters
por: Uettwiller, F, et al.
Publicado: (2016)

Validating 10-joint juvenile arthritis disease activity score cut-offs for disease activity levels in non-systemic juvenile idiopathic arthritis
por: Backström, Maria, et al.
Publicado: (2019)

Genomic risk scores for juvenile idiopathic arthritis and its subtypes
por: Cánovas, Rodrigo, et al.
Publicado: (2020)

Arthropathy of Down syndrome: an under-diagnosed inflammatory joint disease that warrants a name change
por: Foley, Charlene M, et al.
Publicado: (2019)

Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapies
por: Horne, AnnaCarin, et al.
Publicado: (2019)

Immunome perturbation is present in patients with juvenile idiopathic arthritis who are in remission and will relapse upon anti-TNFα withdrawal
por: Leong, Jing Yao, et al.
Publicado: (2019)

Combined genetic analysis of juvenile idiopathic arthritis clinical subtypes identifies novel risk loci, target genes and key regulatory mechanisms
por: López-Isac, Elena, et al.
Publicado: (2021)

Development and reliability of a novel ultrasonographic joint-specific scoring system for synovitis with reference atlas for patients with juvenile idiopathic arthritis
por: Sande, Nina Krafft, et al.
Publicado: (2021)

Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis
por: Lovell, Daniel J, et al.
Publicado: (2021)

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
por: Brunner, Hermine I, et al.
Publicado: (2021)

Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis
por: La, Céline, et al.
Publicado: (2021)

Health-related quality of life and disability in adults with juvenile idiopathic arthritis: comparison with adult-onset rheumatic diseases
por: Oliveira Ramos, Filipa, et al.
Publicado: (2021)

Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis
por: Alongi, Alessandra, et al.
Publicado: (2022)

Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany
por: Sengler, Claudia, et al.
Publicado: (2021)

Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial
por: Gerss, Joachim, et al.
Publicado: (2022)

Procedures for the content, conduct and format of EULAR/PReS paediatric musculoskeletal ultrasound courses
por: Magni-Manzoni, Silvia, et al.
Publicado: (2022)

Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study
por: Montag, Laura J, et al.
Publicado: (2022)

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial
por: Brunner, Hermine I, et al.
Publicado: (2023)

Complications of complications: diagnosis and treatment of recurrent macrophage activation syndrome in a patient with well-controlled systemic juvenile idiopathic arthritis
por: Macaraeg, Marci, et al.
Publicado: (2023)

Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis
por: van Straalen, Joeri W, et al.
Publicado: (2023)

Associations between power Doppler ultrasound findings and B-mode synovitis and clinical arthritis in juvenile idiopathic arthritis using a standardised scanning approach and scoring system
por: Sande, Nina Krafft, et al.
Publicado: (2023)

Patterns of clinical joint inflammation in juvenile idiopathic arthritis
por: Heckert, Sascha L, et al.
Publicado: (2023)

Antibiotic exposure in prenatal and early life and risk of juvenile idiopathic arthritis: a nationwide register-based cohort study
por: Hestetun, Sigrid, et al.
Publicado: (2023)

Children with extended oligoarticular and polyarticular juvenile idiopathic arthritis have alterations in B and T follicular cell subsets in peripheral blood and a cytokine profile sustaining B cell activation
por: Tomé, Catarina, et al.
Publicado: (2023)

Lengthening sleep reduces pain in childhood arthritis: a crossover randomised controlled trial
por: Clairman, Hayyah, et al.
Publicado: (2023)

Human CD56(dim)CD16(dim) Cells As an Individualized Natural Killer Cell Subset
por: Amand, Mathieu, et al.
Publicado: (2017)

Distinct Signatures in the Receptor Repertoire Discriminate CD56bright and CD56dim Natural Killer Cells
por: Schwane, Vera, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v0mehhbv24cfhe6r0rqkc1l054